BioCentury
ARTICLE | Clinical News

BrainStorm starts Ph III of NurOwn to treat ALS

November 3, 2017 4:51 AM UTC

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) began a Phase III trial of NurOwn (MSC-NTF cells) to treat amyotrophic lateral sclerosis (ALS). The double-blind, placebo-controlled, U.S. study will enroll about 200 patients. The primary endpoint is safety, and the secondary endpoint will analyze biomarkers. Top-line data are expected in 2019.

The study is supported by a grant worth $16 million from the California Institute for Regenerative Medicine (CIRM). BrainStorm received a $5.5 million milestone payment, or about 30% of the grant (see BioCentury, Sept. 28)...